{"id":"W2804630302","doi":"10.6000/1929-2279.2018.07.02.3","title":"Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML","year":2018,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Nilotinib; Dasatinib; Tyrosine kinase; Medicine; Philadelphia chromosome; Cancer research; Bosutinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Pharmacology; Internal medicine; Biology; Genetics; Cancer; Chromosomal translocation; Receptor","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008682187,0.0001390836,0.0003409036,0.0003812155,0.000223413,0.0000457133,0.0002215118,0.0000718247,0.001876688],"category_scores_gemma":[0.0001266785,0.0001031967,0.000179096,0.000404075,0.0003722144,0.0002191836,0.00004338604,0.0004799973,0.00006023144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001544773,"about_ca_system_score_gemma":0.001682343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007078731,"about_ca_topic_score_gemma":0.00003365013,"domain_scores_codex":[0.998013,0.0001062806,0.0003957924,0.0001895055,0.0007895195,0.0005058657],"domain_scores_gemma":[0.9970989,0.0002779719,0.0001819247,0.0002010532,0.00194206,0.0002981138],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01014698,0.001462053,0.005938578,0.0004023199,0.005214687,0.0003063318,0.001788717,0.00004046736,0.7031596,0.0009798665,0.2136066,0.05695377],"study_design_scores_gemma":[0.01783232,0.006603271,0.006512413,0.001133805,0.0006706375,0.000571194,0.0003356778,0.0008352487,0.5878215,0.001690335,0.3757336,0.0002599279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9155121,0.02779545,0.0004790015,0.05158578,0.0009173647,0.001817689,0.0002009217,0.00003861504,0.001653047],"genre_scores_gemma":[0.9879171,0.005408023,0.001338166,0.000604918,0.003463058,0.00008998283,0.00001278936,0.00004646025,0.001119545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.162127,"threshold_uncertainty_score":0.9990357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1021393409216489,"score_gpt":0.4858416534499229,"score_spread":0.383702312528274,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}